Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration

T. M. Breslin, K. R. Hess, D. B. Harbison, M. E. Jean, K. R. Cleary, A. P. Dackiw, R. A. Wolff, J. L. Abbruzzese, N. A. Janjan, C. H. Crane, J. N. Vauthey, J. E. Lee, P. W T Pisters, D. B. Evans

Research output: Contribution to journalArticle

295 Citations (Scopus)

Abstract

Background: For patients with potentially resectable pancreatic cancer, the poor outcome associated with resection alone and the survival advantage demonstrated for combined-modality therapy have stimulated interest in preoperative chemoradiotherapy. The goal of this study was to analyze the effects of different preoperative chemoradiotherapy schedules, intraoperative radiation therapy, patient factors, and histopathologic variables on survival duration and patterns of treatment failure in patients who underwent pancreaticoduodenectomy for adenocarcinoma of the pancreatic head. Methods: Data on 132 consecutive patients who received preoperative chemoradiation followed by pancreaticoduodenectomy for adenocarcinoma of the pancreatic head between June 1990 and June 1999 were retrieved from a prospective pancreatic tumor database. Patients received either 45.0 or 50.4 Gy radiation at 1.8 Gy per fraction in 28 fractions or 30.0 Gy at 3.0 Gy per fraction in 10 fractions with concomitant infusional chemotherapy (5-fluorouracil, paclitaxel, or gemcitabine). If restaging studies demonstrated no evidence of disease progression, patients underwent pancreaticoduodenectomy. All patients were evaluated with serial postoperative computed tomography scans to document first sites of tumor recurrence. Results: The overall median survival from the time of tissue diagnosis was 21 months (range 19-26, 95%Cl). At last follow-up, 41 patients (31%) were alive with no clinical or radiographic evidence of disease. The survival duration was superior for women (P = .04) and for patients with no evidence of lymph node metastasis (P = .03). There was no difference in survival duration associated with patient age, dose of preoperative radiation therapy, the delivery of intraoperative radiotherapy, tumor grade, tumor size, retroperitoneal margin status, or the histologic grade of chemoradiation treatment effect. Conclusion: This analysis supports prior studies which suggest that the survival duration of patients with potentially resectable pancreatic cancer is maximized by the combination of chemoradiation and pancreaticoduodenectomy. Furthermore, there was no difference in survival duration between patients who received the less toxic rapid-fractionation chemoradiotherapy schedule (30 Gy, 2 weeks) and those who received standard-fractionation chemoradiotherapy (50.4 Gy, 5.5 weeks). Short-course rapid-fractionation preoperative chemoradiotherapy combined with pancreaticoduodenectomy, when performed on accurately staged patients, maximizes survival duration and is associated with a low incidence of local tumor recurrence.

Original languageEnglish (US)
Pages (from-to)123-132
Number of pages10
JournalAnnals of Surgical Oncology
Volume8
Issue number2
DOIs
StatePublished - 2001

Fingerprint

Chemoradiotherapy
Pancreas
Adenocarcinoma
Survival
Pancreaticoduodenectomy
Therapeutics
Radiotherapy
Neoplasms
gemcitabine
Pancreatic Neoplasms
Appointments and Schedules
Radiation Dosage
Recurrence
Tissue Survival
Combined Modality Therapy
Poisons
Paclitaxel
Treatment Failure
Fluorouracil
Disease Progression

Keywords

  • Chemoradiation
  • Pancreatic cancer
  • Pancreaticoduodenectomy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas : Treatment variables and survival duration. / Breslin, T. M.; Hess, K. R.; Harbison, D. B.; Jean, M. E.; Cleary, K. R.; Dackiw, A. P.; Wolff, R. A.; Abbruzzese, J. L.; Janjan, N. A.; Crane, C. H.; Vauthey, J. N.; Lee, J. E.; Pisters, P. W T; Evans, D. B.

In: Annals of Surgical Oncology, Vol. 8, No. 2, 2001, p. 123-132.

Research output: Contribution to journalArticle

Breslin, TM, Hess, KR, Harbison, DB, Jean, ME, Cleary, KR, Dackiw, AP, Wolff, RA, Abbruzzese, JL, Janjan, NA, Crane, CH, Vauthey, JN, Lee, JE, Pisters, PWT & Evans, DB 2001, 'Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration', Annals of Surgical Oncology, vol. 8, no. 2, pp. 123-132. https://doi.org/10.1245/aso.2001.8.2.123
Breslin, T. M. ; Hess, K. R. ; Harbison, D. B. ; Jean, M. E. ; Cleary, K. R. ; Dackiw, A. P. ; Wolff, R. A. ; Abbruzzese, J. L. ; Janjan, N. A. ; Crane, C. H. ; Vauthey, J. N. ; Lee, J. E. ; Pisters, P. W T ; Evans, D. B. / Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas : Treatment variables and survival duration. In: Annals of Surgical Oncology. 2001 ; Vol. 8, No. 2. pp. 123-132.
@article{4740e16897ff43bda38ce41f9058605e,
title = "Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration",
abstract = "Background: For patients with potentially resectable pancreatic cancer, the poor outcome associated with resection alone and the survival advantage demonstrated for combined-modality therapy have stimulated interest in preoperative chemoradiotherapy. The goal of this study was to analyze the effects of different preoperative chemoradiotherapy schedules, intraoperative radiation therapy, patient factors, and histopathologic variables on survival duration and patterns of treatment failure in patients who underwent pancreaticoduodenectomy for adenocarcinoma of the pancreatic head. Methods: Data on 132 consecutive patients who received preoperative chemoradiation followed by pancreaticoduodenectomy for adenocarcinoma of the pancreatic head between June 1990 and June 1999 were retrieved from a prospective pancreatic tumor database. Patients received either 45.0 or 50.4 Gy radiation at 1.8 Gy per fraction in 28 fractions or 30.0 Gy at 3.0 Gy per fraction in 10 fractions with concomitant infusional chemotherapy (5-fluorouracil, paclitaxel, or gemcitabine). If restaging studies demonstrated no evidence of disease progression, patients underwent pancreaticoduodenectomy. All patients were evaluated with serial postoperative computed tomography scans to document first sites of tumor recurrence. Results: The overall median survival from the time of tissue diagnosis was 21 months (range 19-26, 95{\%}Cl). At last follow-up, 41 patients (31{\%}) were alive with no clinical or radiographic evidence of disease. The survival duration was superior for women (P = .04) and for patients with no evidence of lymph node metastasis (P = .03). There was no difference in survival duration associated with patient age, dose of preoperative radiation therapy, the delivery of intraoperative radiotherapy, tumor grade, tumor size, retroperitoneal margin status, or the histologic grade of chemoradiation treatment effect. Conclusion: This analysis supports prior studies which suggest that the survival duration of patients with potentially resectable pancreatic cancer is maximized by the combination of chemoradiation and pancreaticoduodenectomy. Furthermore, there was no difference in survival duration between patients who received the less toxic rapid-fractionation chemoradiotherapy schedule (30 Gy, 2 weeks) and those who received standard-fractionation chemoradiotherapy (50.4 Gy, 5.5 weeks). Short-course rapid-fractionation preoperative chemoradiotherapy combined with pancreaticoduodenectomy, when performed on accurately staged patients, maximizes survival duration and is associated with a low incidence of local tumor recurrence.",
keywords = "Chemoradiation, Pancreatic cancer, Pancreaticoduodenectomy",
author = "Breslin, {T. M.} and Hess, {K. R.} and Harbison, {D. B.} and Jean, {M. E.} and Cleary, {K. R.} and Dackiw, {A. P.} and Wolff, {R. A.} and Abbruzzese, {J. L.} and Janjan, {N. A.} and Crane, {C. H.} and Vauthey, {J. N.} and Lee, {J. E.} and Pisters, {P. W T} and Evans, {D. B.}",
year = "2001",
doi = "10.1245/aso.2001.8.2.123",
language = "English (US)",
volume = "8",
pages = "123--132",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas

T2 - Treatment variables and survival duration

AU - Breslin, T. M.

AU - Hess, K. R.

AU - Harbison, D. B.

AU - Jean, M. E.

AU - Cleary, K. R.

AU - Dackiw, A. P.

AU - Wolff, R. A.

AU - Abbruzzese, J. L.

AU - Janjan, N. A.

AU - Crane, C. H.

AU - Vauthey, J. N.

AU - Lee, J. E.

AU - Pisters, P. W T

AU - Evans, D. B.

PY - 2001

Y1 - 2001

N2 - Background: For patients with potentially resectable pancreatic cancer, the poor outcome associated with resection alone and the survival advantage demonstrated for combined-modality therapy have stimulated interest in preoperative chemoradiotherapy. The goal of this study was to analyze the effects of different preoperative chemoradiotherapy schedules, intraoperative radiation therapy, patient factors, and histopathologic variables on survival duration and patterns of treatment failure in patients who underwent pancreaticoduodenectomy for adenocarcinoma of the pancreatic head. Methods: Data on 132 consecutive patients who received preoperative chemoradiation followed by pancreaticoduodenectomy for adenocarcinoma of the pancreatic head between June 1990 and June 1999 were retrieved from a prospective pancreatic tumor database. Patients received either 45.0 or 50.4 Gy radiation at 1.8 Gy per fraction in 28 fractions or 30.0 Gy at 3.0 Gy per fraction in 10 fractions with concomitant infusional chemotherapy (5-fluorouracil, paclitaxel, or gemcitabine). If restaging studies demonstrated no evidence of disease progression, patients underwent pancreaticoduodenectomy. All patients were evaluated with serial postoperative computed tomography scans to document first sites of tumor recurrence. Results: The overall median survival from the time of tissue diagnosis was 21 months (range 19-26, 95%Cl). At last follow-up, 41 patients (31%) were alive with no clinical or radiographic evidence of disease. The survival duration was superior for women (P = .04) and for patients with no evidence of lymph node metastasis (P = .03). There was no difference in survival duration associated with patient age, dose of preoperative radiation therapy, the delivery of intraoperative radiotherapy, tumor grade, tumor size, retroperitoneal margin status, or the histologic grade of chemoradiation treatment effect. Conclusion: This analysis supports prior studies which suggest that the survival duration of patients with potentially resectable pancreatic cancer is maximized by the combination of chemoradiation and pancreaticoduodenectomy. Furthermore, there was no difference in survival duration between patients who received the less toxic rapid-fractionation chemoradiotherapy schedule (30 Gy, 2 weeks) and those who received standard-fractionation chemoradiotherapy (50.4 Gy, 5.5 weeks). Short-course rapid-fractionation preoperative chemoradiotherapy combined with pancreaticoduodenectomy, when performed on accurately staged patients, maximizes survival duration and is associated with a low incidence of local tumor recurrence.

AB - Background: For patients with potentially resectable pancreatic cancer, the poor outcome associated with resection alone and the survival advantage demonstrated for combined-modality therapy have stimulated interest in preoperative chemoradiotherapy. The goal of this study was to analyze the effects of different preoperative chemoradiotherapy schedules, intraoperative radiation therapy, patient factors, and histopathologic variables on survival duration and patterns of treatment failure in patients who underwent pancreaticoduodenectomy for adenocarcinoma of the pancreatic head. Methods: Data on 132 consecutive patients who received preoperative chemoradiation followed by pancreaticoduodenectomy for adenocarcinoma of the pancreatic head between June 1990 and June 1999 were retrieved from a prospective pancreatic tumor database. Patients received either 45.0 or 50.4 Gy radiation at 1.8 Gy per fraction in 28 fractions or 30.0 Gy at 3.0 Gy per fraction in 10 fractions with concomitant infusional chemotherapy (5-fluorouracil, paclitaxel, or gemcitabine). If restaging studies demonstrated no evidence of disease progression, patients underwent pancreaticoduodenectomy. All patients were evaluated with serial postoperative computed tomography scans to document first sites of tumor recurrence. Results: The overall median survival from the time of tissue diagnosis was 21 months (range 19-26, 95%Cl). At last follow-up, 41 patients (31%) were alive with no clinical or radiographic evidence of disease. The survival duration was superior for women (P = .04) and for patients with no evidence of lymph node metastasis (P = .03). There was no difference in survival duration associated with patient age, dose of preoperative radiation therapy, the delivery of intraoperative radiotherapy, tumor grade, tumor size, retroperitoneal margin status, or the histologic grade of chemoradiation treatment effect. Conclusion: This analysis supports prior studies which suggest that the survival duration of patients with potentially resectable pancreatic cancer is maximized by the combination of chemoradiation and pancreaticoduodenectomy. Furthermore, there was no difference in survival duration between patients who received the less toxic rapid-fractionation chemoradiotherapy schedule (30 Gy, 2 weeks) and those who received standard-fractionation chemoradiotherapy (50.4 Gy, 5.5 weeks). Short-course rapid-fractionation preoperative chemoradiotherapy combined with pancreaticoduodenectomy, when performed on accurately staged patients, maximizes survival duration and is associated with a low incidence of local tumor recurrence.

KW - Chemoradiation

KW - Pancreatic cancer

KW - Pancreaticoduodenectomy

UR - http://www.scopus.com/inward/record.url?scp=0035093234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035093234&partnerID=8YFLogxK

U2 - 10.1245/aso.2001.8.2.123

DO - 10.1245/aso.2001.8.2.123

M3 - Article

C2 - 11258776

AN - SCOPUS:0035093234

VL - 8

SP - 123

EP - 132

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 2

ER -